Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
When you buy through our links, Business Insider may earn an affiliate commission. Learn more If you want to breeze through airports, train stations, and city streets hands-free, a great travel ...
We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Elissa Sanci Elissa Sanci is a senior writer who has reported on label makers, ...
Nvidia disclosed in recent regulatory filings that it had fully exited its roughly two‑year, 7.71 million‑share investment in Recursion Pharmaceuticals, while Cathie Wood’s ARK Invest simultaneously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results